非增强脑肿瘤患者中ABCB1/ABCG2底物脑内递送的PET评估
该研究用[11C]tariquidar PET在7例非增强脑肿瘤(WHO I-III级)患者中评估血脑肿瘤屏障完整性,发现肿瘤与无肿瘤脑组织的示踪剂分布无显著差异,仅1例出现小范围摄取增高;4例切除组织的ABCG2/ABCB1比值与既往人微血管报道相当,提示所研究肿瘤血脑肿瘤屏障完整,抗癌药需高被动通透性且非ABCB1/ABCG2底物。
要点
- 非增强脑肿瘤(WHO I-III级)中[11C]tariquidar脑分布低,肿瘤与无肿瘤脑组织无显著差异。
- 仅1例患者脑肿瘤内见小范围[11C]tariquidar摄取增高。
- 切除肿瘤组织ABCG2/ABCB1比值为1.4 ± 0.2,与既往人微血管的1.3相当。
核心结论
- 所研究的非增强脑肿瘤血脑肿瘤屏障完整,对双ABCB1/ABCG2底物类抗癌药不通透。
研究设计与样本
- 对7例非增强脑肿瘤(WHO I-III级)患者行[11C]tariquidar PET成像,该示踪剂为原型ABCB1/ABCG2底物。
- 对4例患者手术切除肿瘤组织用定量靶向绝对蛋白质组学测定ABCB1和ABCG2水平。
主要发现
- [11C]tariquidar全脑分布很低,肿瘤与无肿瘤脑组织间无显著差异。
- 仅1例患者脑肿瘤内出现小范围[11C]tariquidar摄取增高。
- 切除肿瘤组织ABCG2/ABCB1比值为1.4 ± 0.2,与既往报道的离体人微血管比值1.3相当。
临床怎么用
- 对非增强脑肿瘤,抗癌药需具备高被动通透性且缺乏ABCB1/ABCG2底物亲和力才可能有效递送。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) are two efflux transporters expressed at the blood-brain barrier which effectively restrict the brain distribution of the majority of currently known anticancer drugs. High-grade brain tumors often possess a disrupted blood-brain tumor barrier (BBTB) leading to enhanced accumulation of magnetic resonance imaging contrast agents, and possibly anticancer drugs, as compared to normal brain. In contrast to high-grade brain tumors, considerably less information is available with respect to BBTB integrity in lower grade brain tumors. MATERIALS AND METHODS: We performed positron emission tomography imaging with the radiolabeled ABCB1 inhibitor [11C]tariquidar, a prototypical ABCB1/ABCG2 substrate, in seven patients with non-contrast -enhancing brain tumors (WHO grades I-III). In addition, ABCB1 and ABCG2 levels were determined in surgically resected tumor tissue of four patients using quantitative targeted absolute proteomics. RESULTS: Brain distribution of [11C]tariquidar was found to be very low across the whole brain and not significantly different between tumor and tumor-free brain tissue. Only one patient showed a small area of enhanced [11C]tariquidar uptake within the brain tumor. ABCG2/ABCB1 ratios in surgically resected tumor tissue (1.4 ± 0.2) were comparable to previously reported ABCG2/ABCB1 ratios in isolated human micro-vessels (1.3), which suggested that no overexpression of ABCB1 or ABCG2 occurred in the investigated tumors. CONCLUSIONS: Our data suggest that the investigated brain tumors had an intact BBTB, which is impermeable to anticancer drugs, which are dual ABCB1/ABCG2 substrates. Therefore, effective drugs for antitumor treatment should have high passive permeability and lack ABCB1/ABCG2 substrate affinity. TRIAL REGISTRATION: European Union Drug Regulating Authorities Clinical Trials Database (EUDRACT), 2011-004189-13. Registered on 23 February 2012, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004189-13.
引用
- Wulkersdorfer B, Bauer M, Karch R, et al. Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. EJNMMI Res. 2019. PMID: 31832814. doi:10.1186/s13550-019-0581-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。